INCERT
12.4.2024 18:40:30 CEST | Business Wire | Press release
Digital public agency INCERT GIE Luxembourg expands to the private sector with today’s launch of Keys&More, a hardware-agnostic enterprise key management system (KMS) designed for the complex deployment needs of manufacturers and industrial providers.
The KMS solution combines (1) a powerful platform for centralized management, (2) flexible deployment options and (3) strategic consulting services. Available via a cloud-based (KMSaaS), on-premises or hybrid option, Keys&More streamlines management of the entire key lifecycle: key preparation, creation, rotation, disabling, archiving and deletion.
Through one user-friendly platform, original equipment manufacturers (OEMs) oversee user management, digital signatures, encryption, decryption and beyond. This unified system helps them achieve compliance, boost operational efficiency, cut costs and apply cryptography best practices.
As a platform-independent solution, Keys&More functions with any cloud provider and multiple HSM and database vendors.
“Our value lies in our customizable deployment options. We know that the reality of cybersecurity can be messy: It’s common for larger organizations to find themselves with a patchwork of diverse processes and tools,” explains Benoit Poletti, Chief Executive Officer, INCERT. “Our solution turns that patchwork into one cohesive KMS. We adapt to the expertise and systems already present within a company, not the other way around. We’re making responsible key management as painless as possible, while unlocking new strategic opportunities.”
Keys&More expects to resonate with the automotive industry due to its (1) complex deployment needs, (2) growing dependence on connected devices and (3) industry regulations. The solution empowers organizations to safely leverage transformative trends, such as Vehicle-to-Everything, the Internet of Things and production line digitalization.
“This product is the result of INCERT’s historical skillset, our years of collaboration with a major automotive technology provider and our engagement with regulatory committees and R&D projects,” explains Sylvain Arts, Chief Business Officer, INCERT. “We really understand the challenges keeping OEMs from streamlining their key lifecycle management. But new regulations, especially in the automotive industry, mean that the adoption of a cohesive KMS solution cannot wait.”
“There is a strong business case for adopting a centralized KMS solution,” adds Benoit Poletti. “Crisis management, market positioning, compliance and auditing processes all improve with Keys&More. Having an efficient KMS in place makes it easier for organizations to scale, adapt and evolve—including, for example, transitioning to a post-quantum environment.”
“INCERT gave us the best value for money,” recalls INCERT’s major automotive industry client. “We could not live without them […]. Before they were an option, now they are a fundamental piece of the infrastructure. [… They were] very good at getting us everything we needed.”
ABOUT INCERT
INCERT was launched by the Government of Luxembourg in 2012 as a public digital services partner focused on critical IT infrastructure & verification of digital signatures. It soon began consulting foreign governments on the topics of public key infrastructure, identity management, standards & cybersecurity. Offering an entire ecosystem of services & solutions, INCERT’s public & private sector projects span the globe. With over a decade’s worth of insight, INCERT has developed its own unified KMS solution: Keys&More.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412187710/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom